We are live on ! Find out more
CYCN icon

Cyclerion Therapeutics
CYCN

15 hedge funds and large institutions have $2.7M invested in Cyclerion Therapeutics in 2024 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 5 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

12% more capital invested

Capital invested by funds: $2.41M → $2.7M (+$285K)

0.33% less ownership

Funds ownership: 38.81% → 38.47% (-0.33%)

12% less funds holding

Funds holding: 17 → 15 (-2)

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

67% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 3

80% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 5

Holders
15
Holders Change
-2
Holders Change %
-11.76%
% of All Funds
0.22%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.01%
New
1
Increased
1
Reduced
5
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Bank of America
Bank of America
North Carolina
+$21

Top Sellers

Rank Fund Capital Flow
1
AG
Artal Group
Luxembourg
-$271K
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$11.1K
3
UBS Group
UBS Group
Switzerland
-$7.53K
4
TRCT
Tower Research Capital (TRC)
New York
-$1.14K
5
BlackRock
BlackRock
New York
-$1.09K
Name Holding Trade Value Shares
Change 		Change in
Stake
SPC
1
Slate Path Capital
New York
$927K – – –
MP
2
MFN Partners
Massachusetts
$437K – – –
TCP
3
Tyndall Capital Partners
New York
$427K – – –
Fidelity Investments
4
Fidelity Investments
Massachusetts
$407K -$11.1K -3,783 -2%
SL
5
Siren LLC
Connecticut
$301K +$342K +116,155 New
Geode Capital Management
6
Geode Capital Management
Massachusetts
$87.5K -$206 -70 -0.2%
Vanguard Group
7
Vanguard Group
Pennsylvania
$60.6K – – –
BlackRock
8
BlackRock
New York
$43.5K -$1.09K -372 -2%
TRCT
9
Tower Research Capital (TRC)
New York
$2.79K -$1.14K -386 -26%
Morgan Stanley
10
Morgan Stanley
New York
$1.68K – – –
Group One Trading
11
Group One Trading
Illinois
$1.39K – – –
UBS Group
12
UBS Group
Switzerland
$376 -$7.53K -2,561 -95%
AWM
13
Activest Wealth Management
Florida
$259 – – –
Bank of America
14
Bank of America
North Carolina
$59 +$21 +7 +44%
Northwestern Mutual Wealth Management
15
Northwestern Mutual Wealth Management
Wisconsin
$3 – – –
AG
16
Artal Group
Luxembourg
– -$271K -117,643 Closed
Royal Bank of Canada
17
Royal Bank of Canada
Ontario, Canada
– -$1K -416 Closed
PNC Financial Services Group
18
PNC Financial Services Group
Pennsylvania
– -$5 -2 Closed

CYCN Hedge Fund Activity: Q3 2024 in Review

15 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Cyclerion Therapeutics (CYCN) for Q3 2024, worth a combined $2.7M — up 12% from $2.41M a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of CYCN and 1 opened new positions — a net loss of 2 holders — while 5 trimmed existing stakes and 1 added.

The largest buyer was Bank of America, adding an estimated $21. The largest seller was Artal Group, exiting entirely with an estimated $271K sold.

  • 15 institutional investors held Cyclerion Therapeutics (CYCN) as of Q3 2024, down from 17 in Q2 2024.
  • Funds reported $2.7M of Cyclerion Therapeutics stock for Q3 2024, up 12% quarter-over-quarter.
  • 1 fund opened new Cyclerion Therapeutics positions in Q3 2024 and 3 closed out, a net change of -2 holders.
  • The largest Cyclerion Therapeutics buyer in Q3 2024 was Bank of America, an estimated $21 added.
  • The largest Cyclerion Therapeutics seller in Q3 2024 was Artal Group, an estimated $271K sold.

Based on aggregated 13F filings for Q3 2024.